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INTRODUCTION
          For a clear image to be formed on the retina, the transparency of cornea 
and lens is essential. Cornea contributes to two-thirds of refractive power and 
lens to one- third of refractive power.
         In the visible range of spectrum (380 to 760 nm), the cornea transmits 
almost 100% of light energy. This transparency is due to 
I. ANATOMICAL  FACTORS 
a) Avascularity of cornea 
b) Absence of pigment in the cornea 
c) Demyelinated nerve supply 
d) Regular arrangement of epithelial and endothelial cells
e) Regular arrangement of stromal collagen fibres 
f) Paucity of cells in stroma 
g) Epithelial cells are non-keratinised 
h) Anterior surface of tears helps in forming a regular refractive surface 
II. RELATIVE DEHYDRATION OF THE STROMA MAINTAINED 
BY
a) Epithelium, which is largely impermeable to water
b) Endothelial transport system to pump fluid from the corneal stroma 
to the aqueous by Na –K ATPase mechanism.
c) Special intercellular junction in endothelium 
III. MAINTENANCE  OF  NORMAL  INTRAOCULAR 
PRESSURE 
              The  lens  is  a  transparent  crystalline  structure,  covered  by a 
homogenous capsule and has epithelium only beneath the anterior capsule.  
It transmits almost 80% of light energy. Its transparency is due to 
i) Sparsity of cells 
ii)  Single layer of epithelial cells, which is not thick 
iii) Close alignment of individual cells 
iv)  Impermeable character of the lens capsule
v) Avascularity 
vi) Same index of refraction in all parts of the lens   
vii) Pump mechanism of the lens fibre membranes, which maintains 
relative dehydration of the lens 
viii) Auto-oxidation – High concentration of reduced glutathione in 
the  lens,  maintains  the  lens  proteins  in  a  reduced  state  and 
ensures the integrity of cell –membrane pump.
Opacities  or  pigmentation  affecting  transparency  of  cornea  and  lens 
occurs as a result of aging and usage of drugs.
There  are  certain  psychotic,  Rheumatological,  Collagen  Vascular, 
Dermatological, Immunological, Cardiac conditions requiring drug therapy for 
a shorter or longer period of time. These group of drugs have a tendency to 
cause corneal and lenticular opacities or pigmentation which may or may not 
affect vision.
The prevalence of mental illness in general population is 9-10%, & for 
schizophrenia  it  is  1%.  Other  than  schizophrenia,  condition  like  mental 
retardation with behavioural problems, substance induced psychosis (cannabis, 
alcohol),  certain  types  of  manic  depressive  psychosis   requires  long  term 
treatment with chlorpromazine  inspite of newer anti -psychotic  drugs . 
There  are  reported  incidence  of  corneal  and  lenticular  pigmentation 
following long term chlorpromazine therapy  which usually  does not affect 
vision.
To perform social responsibilities, mentally ill patients need to have an 
independent life pattern to carry on their own duties.
I selected this topic to evaluate the incidence of corneal and lenticular 
pigmentation or opacity with dose and duration of long term chlorpromazine 
therapy and its significance in causing visual defects.
DEVELOPMENT OF CORNEA AND DRUG RELATED 
CORNEAL OPACITIES OR PIGMENTATION
  Cornea develops from interaction of surface ectoderm derived epithelium and 
neural crest derived mesenchyme, which gives rise to deeper layers including 
Bowmans layer, stroma, endothelium and its thick basal lamina, Descemet’s 
membrane.
            Photosensitising agents absorb visible and UVrays and as a result 
generate  free  radicals.  These photosensitizing agents  may become bound to 
macromolecules in the cornea, lens and retina which also act as drug depots. 
Once the therapeutic agent has circulated through uveal tract into aqueous, it 
can rapidly penetrate the corneal epithelium and deposit in the stroma, or if 
lipophilic, it accumulates in the corneal epithelium. 
DEVELOPMENT OF LENS, AGE RELATED AND DRUG 
RELATED OPACITIES OR PIGMENTATION ON LENS
           The normal human lens originates from a double layer of epithelium . Its  
thickened outer basal lamina (the capsule) is analogous to Descemet’s layer. 
The lens grows to become a thick, flexible tissue composed of cells densely 
packed with clear protein known as crystallins. By the age of 50 yrs, flexibility 
is  reduced,  thus  diminishing  the  accommodation.  The  capsule  reaches  the 
thickness of several microns anteriorly and is ten times thinner posteriorly.
The  anterior  lens  epithelium is  the  most  active  region  metabolically 
conducting cation transport and cell division. The region is also the most prone 
to damage from drugs or toxic substances.
The lens grows with age and colouration or opacities may develop and 
interfere the vision. Cataract formation may be enhanced by miotics, steroids, 
and phenothiazines.
The  eye  because  of  its  rich  blood supply  and relatively  small  mass, 
exhibits an unusually high susceptibility to toxic substances. Drug molecule 
present in systemic circulation can reach ocular structures by way of the uveal 
or retinal vasculature, once in the eye drugs and chemicals can be deposited in 
several anatomic sites acting as drug deposits such as cornea, lens, and retina.
The binding ability of drugs to melanin can lead to ocular toxicity. The 
free radical nature of melanin which is present in ocular tissue such as uveal 
tract and retinal pigment epithelium may contribute to binding capacity of drug 
such as chlorpromazine and haloperidol.
DRUGS  CAUSING  CORNEAL  DEPOSITS  OR OPACITIES  OR 
PIGMENTATION                                                  
A.  CHLOROQUINE  AND  HYDROXYCHLOROQUINE 
i.  EARLY STAGE
            Diffuse, Punctate deposits appear in the corneal epithelium.
ii. LATE STAGE
           Deposits aggregate into curved line that converge and coalesce below 
the central cornea.
iii. FINAL STAGE
           Green, Yellow pigmented lines appear in the centre of the cornea as a 
whorl like opacity.
Visual  acuity  usually  remains  unchanged  on  discontinuation  of  the 
therapy both subjective and objective corneal signs disappear. 
 Keratopathy  occurs  in  30%  to  75%  of  patients  treated  with  either 
chloroquine or hydroxychloroquine, but corneal change are found much less 
frequently in patients treated with hydroxychloroquine.
Corneal  deposits  observed  as  early  as  2  to  6  weeks  after  beginning 
therapy  and  there  is  no  relationship  between  the  development  of  corneal 
deposits and the occurence of retinopathy.
The  origin  of  the  corneal  opacities  appears  to  be  due  to  reversible 
binding of the drug to intra cellular nucleo proteins. The changes are limited to 
the corneal epithelium, which the drug may reach by deposition in tear film or 
limbal vasculature.
B)  CHLORPROMAZINE
                The pigmentation is white, yellow-white, brown or black and occurs 
at the level of the endothelium and Descemet’s membrane primarily in the inter 
palpebral fissure area. In severe cases it can affect deep stroma.
C)   INDOMETHACIN 
It  appears  as  a  whorl  like  distribution  resembling  that  seen  in 
chloroquine keratopathy. These corneal changes diminish or disappear within 6 
months of discontinuing indomethacin therapy. They are seen in patients taking 
indomethacin  for  12  to  18  months  with  the  daily  doses  ranging  from  
75 to 200mg.
The  mechanisms  of  these  opacities  is  unknown.  Patients  are  usually 
asymptomatic.
D) GOLD  SALTS 
Corneal chrysiasis  consists  of  the  presence of numerous minute gold 
particles  appearing as  yellowish brown to violet  or  red particles  distributed 
irregularly  in  the  stroma.  The  deposition  of  the  gold  generally  spares  the 
peripheral 1 to 3 mm as well as superior ¼ to ½ of cornea and the deposits tend 
to  localize  to  the  posterior  one  third  of  the  stroma.  There  is  typically  no 
involvement of epithelium, Descemet’s membrane or epithelium.
Corneal chrysiasis is a common finding in patients receiving long term 
gold maintenance therapy for Rheumatoid arthritis . Deposits are found in 97% 
of patients receiving continuous gold therapy consisting of cumulative dosage 
of atleast 1000 mg.
Gold is deposited in the cornea and lens by circulation in the aqueous 
fluid in the anterior chamber. Deposits do not cause any visual disturbance.
E) AMIODARONE 
i. Grade I :
          A faint, horizontal line similar to a Hudson stahli line appear in the 
interpalpebral  fissure  at  the  junction  of  the  middle  and  lower  third  of  the 
cornea . It consists of golden brown micro deposits in the endothelium first 
anterior to Bowmans layer.                   
ii Grade II :
         Transition to this stage occurs by 6 months , during which time deposits 
become aligned in a more linear pattern and extends towards the limbus .The 
Grade II pattern does not necessarily progress to Grade III .
iii. Grade III :
         The deposits increase in number and density and lines extend superiorly 
to produce a whore like pattern into visual axis.
iv. Grade IV :
          Irregular round clumps of deposits .
The  keratopathy  gradually  resolves  within  6  to  18  months  after 
discontinuation of  the drug therapy.  Patients  taking higher  dosages  (400 to 
1400  mg daily)  demonstrate  more  advanced keratopathy  depending on  the 
duration of the treatment
F) ATOVAQUONE 
          An  anti- parasitic drug used to treat pneumonia in patients intolerant to 
trimethoprim - sulfamethoxazole, cause vorticilate keratopathy in susceptible 
patients .
         Slit lamp examination shows bilateral whorl like patterns involving the 
inferior central corneal epithelium, with normal stroma and endothelium.
The  vortex  pattern  is  probably  a  result  of  growth  and  repair  of  corneal 
epithelium, with the flow of cells from peripheral to central cornea creating a 
whorl like configuration.
Keratopathy  subsides  once  the  drug  is  discontinued,  and  there  is 
minimal risk of long term visual impairment.
G) ISOTRETINOIN 
An analogue of vitamin A -Isotretinoin is used for the control of severe 
recalcitrant cystic acne and other keratinizing dermatoses.
It causes keratitis , corneal opacities  and corneal vascularisation.
Epithelial keratitis has been reported in patients treated with an average 
dose of 2mg /  kg for various dermatological  diseases.  Subepithelial  corneal 
opacities may occur in both central and peripheral cornea and if the visual axis 
is involved, vision may be impaired.
Suppression of meibomian gland activity can also cause deficiency of 
normal lipid layer of the pre ocular tear film. This can lead to evaporation of 
aqueous  layer  and  subsequent  drying  of  the  ocular  surface,  followed  by 
epithelial and subepithelial defects. 
DRUGS CAUSING LENTICULAR
PIGMENTATION OR OPACITIES
1) CORTICOSTEROIDS 
The use of systemic, topical ophthalmic, topical dermatologic and nasal 
aerosol  or  inhalation  steroids  cause  posterior  subcapsular  cataract.  Initially 
these opacities develop followed by anterior subcapsular opacity.                  
The  relationship  between  weekly  systemic  dose,  duration  of 
administration, total dose and cataract formation is unclear. It is thought that 
patients on less than 10 mg prednisolone (or equivalent) or treated for less than 
4 years, may be immune. Although it is believed that children may be more 
susceptible  to  the  cataractogenic  effects  of  systemic  steroids.  Individual 
(genetic) susceptibility may also be of relevance.
Patients who develop lens changes should have their dosages reduced to 
a minimum consistent with control of underlying disease, and if possible be 
considered for alternate drug therapy. Early opacities may regress if therapy is 
withdrawn,  alternatively  progression  may  occur  despite  withdrawal  and 
warrant surgical intervention.
2) CHLORPROMAZINE
It  causes  deposition  of  innocuous,  fine,  stellate,  yellowish,  brown 
granules on the anterior lens capsule within the pupillary area.
Diffuse, granular deposits on the corneal endothelium and in the deep 
stroma may occur.
Both  lenticular  and  corneal  deposits  are  dose  related  and  usually 
irreversible.  In  very  high  doses  (>2400  mg/day),  this  drug  may  cause 
retinotoxicity.
3) BUSULPHAN
It  is  used  in  the  treatment  of  chronic  myeloid  leukemia,  may 
occasionally cause lens opacities.
4) AMIODARONE
It  is  a  benzofurone  derivative,  used  to  treat  a  variety  of  cardiac 
abnormalities. The drug is highly effective in the treatment of both atrial and 
ventricular arrythmias and Wolf –Parkinson-White syndrome. Amiodarone can 
cause keratopathy and anterior subcapsular lens opacities early in the course of 
treatment.
Fine anterior subcapsular lens opacities occur in approximately 50% of 
patients taking amiodarone in moderate to high dosages (600 to 800mgdaily) 
after 6 to 18 months of treatment.
The  deposits  first  appear  as  small,  golden  brown  or  white–yellow 
punctate opacities located just below the anterior lens capsule. They are packed 
loosely and cover an area greater than 2mm within the pupillary aperture. The 
opacities are less darkly pigmented and are limited to the superficial anterior 
subcapsular area.
These  lenticular  opacities  usually  cause  no  visual  symptoms,  but 
moderate to severe keratopathy can lead to complaints of blurred vision, glare, 
haloes around lights or light sensitivity.
5) GOLD SALTS
 Both  parenteral  and  oral  gold  salts  are  used  in  the  treatment  of 
Rheumatoid Arthritis. After prolonged administration, gold can be deposited in 
various tissues of the body, a condition known as chrysiasis.
Lenticular  chrysiasis  appears  as  fine,  dust  like,  yellowish  glistening 
deposits in the anterior capsule or in the anterior suture lines. Oral Auronofin is 
deposited in the anterior subcapsular region.
         There  is  no significant  correlation  between corneal  chrysiasis  and 
lenticular chrysiasis, and there is no evidence that gold therapy leads to cataract 
formation.  Deposits  of  gold  in  the  cornea  or  lens  do  not  cause  visual 
disturbances or other symptoms.
6) ALLOPURINOL
It is used in the treatment of hyperuricemia and chronic gout, increases 
the risk of cataract formation in elderly patients, if the cumulative dose exceeds 
400 g or duration of administration exceeds 3 years.
HISTORY OF EVOLUTION OF ANTI -PSYCHOTIC DRUGS 
During  the  past  50  yrs  psychiatric  treatment  has  witnessed  major 
changes  due  to  advent  of  drugs  which  can  have  specific  salutary  effect  in 
mental illness.
The introduction of chlorpromazine in 1952 has transformed the lives of 
schizophrenics, more of them rehabilitated to productive life.
Reserpine  was  discovered  soon  after,  though  it  has  been  powerful 
pharmacological  agent  to  study  mono  aminergic  systems  in  brain  and 
periphery, its clinical use in psychiatry lasted only few years.
The tricyclic and monoamine oxidase antidepressants were introduced in 
1957-58.
Meprobomate  (1954) aroused the hope that anxiety could be tackled 
without producing marked sedation.
The  introduction  of  Chlordiazepoxide  in  1957  and  other 
Benzodiazepines in 1960’s namely Buspirone are subsequent additions.
The introduction of Lithium in 1949 and its effective use began from 
1960’s has unique place in psychiatry.
To the  existing  typical  neuroleptics,  atypical  neuroleptics  are  getting 
added in recent years.                 
COMMONLY USED ANTI-PSYCHOTICS
PHENOTHIAZINES     USUAL DOSE/DAY   MAXIMUM DOSE/DAY
Chlorpromazine               100-400 mg/day                1 g
Thioridazine                      100-400 mg/day              600 mg 
Trifluperazine                   5-15 mg/day                    60 mg 
Fluphenazine                 2- 10 mg/day                      60 mg 
DIBENZODIAZEPINES
Clozapine                         300-400 mg/day               900 mg
BUTYROPHENONE
Haloperidol                     2-5 mg/day                        60 mg 
BENZISOXAZOLE
Risperidone                     2-6 mg/day                       10 mg
THIENBENZODIAZEPINE
Olanzapine                       5-10 mg/day                    10 mg 
CHLORPROMAZINE
It  is  the  antipsychotic  drug belonging to  phenothiazine group having 
aliphatic side chain.
MECHANISM OF ACTION 
It has potent dopamine D2 receptor blocking action along with blockage 
of D1, D3 and D4 blockage action. Blockage of dopaminergic projections to 
the  temporal  and  prefrontal  areas  constituting  the  limbic  system  and  in 
mesocortical areas is probably responsible for antipsychotic action.
THERAPEUTIC USES
- Primarily in functional psychoses -schizophrenia
- Controls positive symptoms (hallucinations, delusions, disorganized 
thought,  restlessness,  insomnia,  anxiety,  aggression  better  than 
negative  symptoms  (apathy,  loss  of  insight  and  volition,  affect, 
flattening, poverty of speech, social withdrawal).
- They cause little improvement in judgement, orientation and memory. 
Patients with recent onset of illness respond better.
- Drug  of  choice  in  AGITATIVE,  VIOLENT  and  COMBATIVE 
PATIENT.
- In mania, for rapid control.
- In organic  brain syndrome,  used on a  short  term basis  one of  the 
potent drugs preferred to avoid mental  confusion,  hypotension and 
precipitation of seizures.
II.  Anxiety
It  should not be used for simple anxiety. Those not responding to or 
having a psychotic basis for anxiety may be treated with these drugs.
III. As Antiemetics 
 Other uses 
a) Pre-anaesthetic medication 
b) To potentiate hypnotics, analgesics and anaesthetics.
c) Intractable hiccough.
d) Tetanus 
e)  Alcoholic  hallucinosis,  Huntington’s  disease  and  Gille’s  De  La 
Tourette  syndrome 
PHARMACOKINETICS OF CHLORPROMAZINE
Oral absorption of chlorpromazine is unpredictable and bioavailability is 
low.
More consistent effects are produced after intramuscular or intravenous 
administration. It is highly bound to plasma as well as tissue proteins. Brain 
concentration is higher than plasma concentration. Volume of distribution is 
large (20 l/kg). It is metabolised in liver into a number of metabolites.
The  acute  effects  of  a  single  dose  generally  lasts  6-8  hours.  The 
elimination half life is in the range of 30 hours. The drug cumulates on chronic 
administration and it is possible to give the total maintenance dose once a day. 
Some metabolites are potentially active.
The intensity  of  antipsychotic  action is  poorly  correlated with plasma 
concentration. The metabolites are excreted in urine and bile for months after 
discontinuing the drug.
OCULAR SIDE EFFECTS OF CHLORPROMAZINE
1)  LENTICULAR PIGMENTATION
5 GRADES 
Grade I->  Earliest sign of lenticular toxicity is fine, dot like opacities on 
the anterior lens surface. At this stage, pigmentary deposits are small and tend 
to assume a disciform distribution within the pupillary area.
Grade II->  Dot like opacities that are denser and more opaque .
Grade III->  Large granules  of  pigment  with an anterior  subcapsular 
stellate  pattern  is easily recognized .
Colour of the opacities ranges from white to yellow to tan. The stellate  pattern 
has a dense central area with radiating branches.
Grade  IV-> A readily  visible  stellate  pattern  with  three  to  nine  star 
points . The lens changes at that stage can be recognized with pen light.
Grade  V-> Central  lightly  pigmented,  pearl  like  opaque  mass 
surrounded by smaller clumps of pigment.
Corneal  pigmentary  changes  are  usually  present  in  patients  who  are 
having grade III and above lenticular pigmentary changes. 
           The pigmentation is white, yellow –white, brown or black and occurs at 
the  level  of  the  endothelium and   Descemet’s  membrane,  primarily  in  the 
interpalpebral fissure and in severe cases, it affects the deep stroma.
 The most prevalent ocular side effect associated with chlorpromazine 
therapy is anterior capsular and subcapsular pigmentation followed by corneal 
endothelial pigmentary changes. Both conditions, however, rarely reduce visual 
acuity and patients may occasionally  report glare, haloes around lights or hazy 
vision.
 Usually,  the  corneal  and lenticular  pigmentary  changes  progress  to  a 
point  beyond  which  no  further  changes  are  observed.  On  reduction  or 
discontinuation  of  drug  therapy,  the  pigmentary  changes  are  generally 
irreversible. This is because the deposits are located in avascular tissues .
 The  ocular  changes  associated  with  chlorpromazine  are  dose  related. 
Lenticular pigmentation is  rarely evident when the total  dosage is  less  than 
500g, and the prevalence of pigmentary changes increases with total dosages 
between 1000 and 2000 g,  until  90% of  patients  demonstrate  pigmentation 
when total dosage  exceeds 2500g.
           If daily dosage exceeds 800 mg, lenticular pigmentation as early as 14 to  
20  months  of  therapy.  Dosages  consisting  of  2000  mg  daily  have  caused 
lenticular change in as little as 6 months of therapy.
Corneal pigmentation has been reported to occur within 6 months of 
therapy in 12 % of patients receiving 2000mg of chlorpromazine  daily, but in 
only 1% of patients receiving 300mg of chlorpromazine daily .
An  accepted  hypothesis  for  pigmentary  granules  is  that  pigmentary 
changes are a result of drug interactions with UV light as it passes through the 
cornea and lens, causing exposed proteins to denature, opacify and accumulate 
in the anterior subcapsular  region  of the lens as well as stroma . 
This  explains  why  the  keratopathy  is  localized  to  the  interpalpebral 
fissure area . Other ocular side effects:-
1) Slate blue discolouration of conjuctiva and cornea
2) Decreases aqueous tear secretion
3) Mydriasis 
4)Cycloplegia
5)Increase IOP
6)Pigmentary retinopathy 
AIM OF THE STUDY
1) To evaluate the incidence of lenticular and corneal pigmentation with 
dose and duration of chlorpromazine therapy.
2 To evaluate the significance of  lenticular and corneal pigmentation in 
causing visual defects .
MATERIALS AND METHODS
This clinical study was done to evaluate the incidence of corneal and 
lenticular pigmentation in patients with long term chlorpromazine therapy and 
its significance in causing visual defects.
The study design was a cross-sectional study conducted in  Institute of 
Mental Health , Ayanavaram, Chennai.
 The  patients  included  in  this  study  were  in-patients  residing  in  the 
Institute of Mental Health .
            A total of 100 patients, 50 males and 50 female patients were studied.
             The study was done during the period between June and September 
2006.
            The patients included in the study had the following problems :-
1. Chronic schizophrenia- various subtypes 
2. Mild mental retardation with behavioural problems 
3. Bipolar disorder-manic depressive psychosis
4. Substance induced psychosis(alcohol,cannabis)
All  the  selected  patients  are  on  multi  drug  regimen  with  tablet 
chlorpromazine as one of its component  (Benzhexol, Risperidone, Olanzapine, 
Haloperidol, Trifluoperazine).
EXCLUSION CRITERIA
1. Those who are on chlorpromazine therapy for a period of less than 6 
months duration
2. Those who are  receiving drugs  such as steroids,  indomethacin,  gold, 
atovaquone,  isotretinoin,  amiodarone,  allopurinol  and  antimetabolites 
for  co-morbid  illness  which  may  also  lead  to  corneal  and  lenticular 
pigmentation or opacities
3. Those who are uncooperative 
 While selecting patients for study, particulars such as their name, age, 
sex and diagnosis was recorded.
         Dosage of the drug, chlorpromazine was recorded in terms of following:-
1. Single morning dose/divided dose /maintenance dose/night dose
2. Duration of drug therapy
3. Increase /decrease in the dosage of drug therapy 
4. Continuous /intermittent therapy 
5. Complete stoppage of chlorpromazine/switch over to other 
antipsychotic drug.
History regarding highly restricted outdoor activity elicited from ward 
doctors, staff nurse, and hospital workers.
Patients evaluated for :-
1. Unaided  visual  acuity  & improvement  with  pin  hole  using  snellen’s 
chart
2. Elicitation of ocular movements
3. Skin of lids – look for pigmentation  or discolouration
4. Skin of palpebral fissure for depigmented patches 
5. Bulbar conjunctiva
6. Cornea for opacities or pigmentation
7. Pupil -size, reaction to direct and consensual light reflex
8. Lens for pigment deposition or opacification in particular anterior 
subcapsular and capsular area
9.  Intraocular pressure measurement digitally 
10.  Detailed fundus examination .
Examination  from  step  2  to  8  was  done  initially  with  torch  light, 
followed by  Slit lamp examination.
OBSERVATION AND RESULTS
MALE PATIENTS
TOTAL  NUMBER - 50
AGE DISTRIBUTION
Table No. 1
AGE GROUP NUMBER OF PATIENTS
21- 30 years 8(16%)
31-40 years 16(32%)
41-50 years 21(42%)
51-60 years 5(10%)
TOTAL 50
About 52 % of patients in this study are more than 40 years
DURATION OF THERAPY
Table No. 2
DURATION OF THERAPY NUMBER OF PATIENTS
15 -20 years 5(10%)
10 -15 years 15 ( 30%)
5-10 years 12(24%)
2-5 years 10(20%)
6 months to 2 years 8(16%)
TOTAL 50
About 40% of patients in this study are in hospital for a period of 
more than 10 years.
LIST OF PATIENTS WHO HAD PIGMENTATION OR    
OPACITIES  (CORNEAL AND LENTICULAR) IN GENERAL
Table No. 3
DOSAGE OF 
THERAPY
DURATION OF 
THERAPY
NUMBER OF 
PATIENTS
50-300mgs /day 15-20 years 4(23.5%)
100-200mgs/day 10-15 years 9(53%)
100-200mgs/day 5-10 years 2(11.6%)
100-300mgs /day 2-5 years 2(11.6%)
TOTAL 17
          Out  of  50 patients,  17 patients  (34%) had lenticular  and corneal  
pigmentation for which dose and duration of therapy ranged from as early as 
100-300mgs/day for a period of 2 to 5 years in 2 patients to as long as  50 -300 
mgs /day for 15 to 20 years in  4 patients.
Of the pigmentation positive cases, 9 patients (53%) were on 
100-200mg/day for a period of 10-15 years
LIST OF PATIENTS WHO DID NOT HAVE PIGMENTATION  OR 
OPACTIES(CORNEAL  AND LENTICULAR) IN GENERAL
Table No. 4
DOSAGE OF 
THERAPY
DURATION OF 
THERAPY
NUMBER OF 
PATIENTS
50-200 mgs/day 15-20 years 1(3%)
50-200 mgs/day 10-15 years 6(18%)
50-200mgs/day 5-10 years 10(30%)
50-150mgs/day 2-5 years 14(40%)
50 -150mgs/day 6 months -2 years 2(6%)
TOTAL 33
            Out of 50 patients, 33 patients (66%) did not have lenticular and or 
corneal  pigmentation  /  opacities,  for  which  dosage  and duration  of  therapy 
ranged as early as 50 -150 mgs/day between 6 months -2 years in 2 patients to 
as late as 50-200 mgs /day for 15 -20 years in 1 patient.
Even 6 patients who had treatment for a period of 10-15 years with a 
dosage of 50-200mgs/day did not have pigmentation in cornea and lens.
RIGHT EYE VISUAL ACUITY IN PIGMENTATION   
POSITIVE CASES
Table No. 5
VISUAL ACUITY NUMBER OF PATIENTS
6/6 to 6/6p with PH 6/6 3 (17%)
6/9 to 6/9p with PH 6/6 3 (17%)
6/12 to 6/12p with PH  6/6 5(29.4%)
6/18 to  6/18p with PH 6/6 4(23.5%)
6/24 to 6/24p with PH  6/6 0(0%)
6/36 to 6/36p with PH 6/6 0(0%)
1/60 to 6/60 NIP 2(11.7%)
TOTAL 17
        About 29 % of patients had visual acuity of 6/12 to 6/12p improving  
with pin hole to 6/6. 10 out of 17 patients had visual acuity of 6/18 to 
6/18p and above improving with pin hole to 6/6. 2 patients had visual 
acuity less than 6/60 NIP, of which one had alternate divergent squint and 
for  the  other  it  was  grade  IV  lenticular  pigmentation  with  corneal 
pigmentation associated with immature cataract.
LEFT EYE VISUAL ACUITY IN PIGMENTATION OR OPACITIES 
(CORNEAL  AND LENTICULAR) POSITIVE CASES
Table No. 6
VISUAL ACUITY NUMBER OF  PATIENTS
6/6 to 6/6p with PH 6/6 3(17%)
6/9 to 6/9p with PH 6/6 7(40%)
6/12 to 6/12p with PH 6/6 4(23.5%)
6/18  with PH 6/6 1(5.8%)
6/24 to 6/24p with PH 6/6 0
6/36  NIP 1(5.8%)
1/60 NIP 1(5.8%)
TOTAL 17
          About 40% of patients had visual acuity of 6/9 to 6/9p improving with 
pin  hole  to  6/6.  15  out  of  17  patients  had  visual  acuity  of  6/18  to  6/18p 
improving with pin hole to 6/6.
         One patient had visual acuity of 6/36 NIP because of associated alternate  
divergent squint and other had visual acuity of 1/60 NIP because of immature 
cataract. 
RIGHT EYE VISUAL ACUITY IN PIGMENTATION/OPACITIES 
(CORNEAL AND LENTICULAR) NEGATIVE CASES
Table No. 7
VISUAL ACUITY NUMBER OF PATIENTS
6/6 to 6/6p with PH 6/6 9 (27.2%)
6/9 to 6/9p with PH 6/6 5( 15.15%)
6/12 to 6/12p with PH 6/6 2(6%)
6/18 to 6/18p with PH 6/6 7(21.2%)
6/24 to 6/24p with PH  6/12 to 6/9 5 (15.1%)
6/36 to 6/36p NIP 2(6%)
6/60 to 1/60 NIP 3(9%)
TOTAL 33
      About 27% of patients had visual acuity of 6/6 to 6/6p improving with pin 
hole  to  6/6.23  out  33  patients  (69%)  had  visual  acuity  of  6/18  to  6/18p 
improving with pin hole to 6/6.
     5  patients  (15  %)  had  visual  acuity  of  6/36  to  1/60  NIP  because  of 
associated immature cataract.
     
LEFT EYE VISUAL ACUITY IN PIGMENTATION OR OPACITIES 
(CORNEAL AND LENTICULAR) NEGATIVE CASES IN GENERAL
Table No : 8
VISUAL ACUITY NUMBER OF PATIENTS
6/6 to 6/6p with PH 6/6 8 (24.2%)
6/9 to 6/9p with PH 6/6 4 (12.1%)
6/12 to 6/12p with PH 6/6 10 (30.3%)
6/18 to 6/18p with PH 6/6 3 (9%)
6/24 to 6/24p with PH 6/12 2 (6%)
6/36 to 6/36p NIP 2 (6%)
6/60 to 1/60 NIP 4 (12.1%)
TOTAL 33 patients
       About 30% of patients had visual acuity of 6/12 to 6/12p improving with 
pin hole to 6/6. 25 out of 33 (80%) had visual acuity of 6/18 t0 6/18p and above 
improving with pin hole to 6/6.  4 patients had reduced visual acuity because of 
associated immature cataract.
LATERALITY OF LENTICULAR PIGMENTATION
Table No : 9
LATERALITY NUMBER OF PATIENTS
Bilateral 13 (76.4%)
Unilateral 4 (23.5%)
TOTAL 17
        In about  76% of patients  lenticular pigmentation was bilateral.  The 
involvement  was  unilateral  in  rest  of  the  patients,  of  which  one  had 
pseudophakia, one had adherent leucoma.
RIGHT EYE – NO. OF PATIENTS IN VARYING GRADES OF 
LENTICULAR PIGMENTATION AMONG POSITIVE CASES
Table No : 10
GRADES NUMBER OF PATIENTS
V 9 (56.2%)
IV 0 (0 % )
III 7 (43.7% )
II 0 ( 0% )
I 0 ( 0% )
TOTAL 16
About  56%  of  patients  had  Grade  V  lenticular  pigmentation  among 
positive cases.
          
LEFT EYE – NO OF PATIENTS IN VARYING GRADES OF 
LENTICULAR PIGMENTATION AMONG POSITIVE CASES
Table No : 11
GRADES NO OF PATIENTS
V 8 ( 50% )
IV 4 (25%)
III 3 (18.7%)
II 1 (6.3%)
I 0 (0%)
TOTAL 16
       About  50% of patients  had Grade V lenticular  pigmentation among 
positive cases.
RIGHT EYE
GRADE -V     - 9  PATIENTS
Table No - 12
VISUAL   ACUITY NUMBER OF   PATIENTS
6/6 to 6/6p with PH 6/6 2 (22.2%)
6/9 to 6/9p with PH 6/6 0 (0%)
6/12 to 6/12p with PH 6/6 2 (22.2%)
6/18 to 6/18p with PH 6/6 2 (22.2%)
6/24 to 6/24p with PH 6/12 2 (22.2%)
6/36 to 6/36p NIP 1 (11.1%)
6/60 to 1/60 NIP 0 (0%)
TOTAL 9
          About two third of the patients in Grade V lenticular pigmentation had 
visual acuity of 6/18 to 6/18p and above improving with pin hole to 6/6. Rest of 
the patients had low visual acuity that was attributed to immature cataract and 
age related lens changes.
RIGHT EYE
GRADE - III   -  7  PATIENTS
Table No - 13
VISUAL ACUITY NUMBER OF PATIENTS
6/6 to 6/6p with PH 6/6 2 (28.2%)
6/9 to 6/9p with PH 6/6 1 (14.1%)
6/12 to 6/12p with PH 6/6 2(28.2%)
6/6 to 6/18p with PH 6/6 1 (14.1%)
6/24 to 6/24p with PH6/12 1 (14.1%)
6/36 to 6/36p NIP 0 (0%)
6/60 to 1/60 NIP 0 (0%)
TOTAL 7
       About 80% of the patients in Grade III lenticular pigmentation had visual 
acuity of 6/18 to 6/18p and above improving with pin hole to 6/6.
LEFT EYE
GRADE – V  -  8 PATIENTS
Table No -14
VISUAL   ACUITY NUMBER OF PATIENTS
6/6 to 6/6p with PH 6/6 2 (25%)
6/9 to 6/9p with PH 6/6 4 (50%)
6/12 to 6/12p with PH 6/6 1 (12.5%)
6/18 to 6/18p with PH 6/6 1 (12.5%)
6/24 to 6/24p with PH 6/12 0 (0%)
6/36 to 6/36p NIP 0 (0%)
6/60 to 1/60 NIP 0(0%)
TOTAL 8
      Almost all patients had visual acuity of 6/18 to 6/18p and above improving 
with pin hole to 6/6.
GRADE  - IV  -  4  PATIENTS
Table No - 15
VISUAL ACUITY NUMBER OF PATIENTS
6/6 to 6/6p with PH 6/6 0 (0%)
6/9 to 6/9p with PH 6/6 1 (25%)
6/12 to 6/12p with PH 6/6 1 (25%)
6/18 to 6/18p with PH 6/6 0 (0%)
6/24 to 6/24p with PH 6/12 0 (0%)
6/36 to 6/36p NIP 1 (25%)
6/60 to 1/60 NIP 1 (25%)
TOTAL 4
          About 50% of the patients had visual acuity of 6/12 to 6/12p and above 
improving with pin hole. In rest of the patients visual acuity was reduced due to 
associated alternate divergent squint and immature cataract.
GRADE – III   -  3 PATIENTS
Table No - 16
VISUAL  ACUITY NUMBER OF PATIENTS
6/6p with PH 6/6 1 (33%)
6/12 to 6/12p with PH 6/6 2 (66%)
TOTAL 3
        Almost all the patients in Grade 3 lenticular pigmentation had visual 
acuity of 6/12 to 6/12p and above improving with pin hole to 6/6.
GRADE  - 2  -  1 PATIENT   6/9p with pin hole 6/6
LATERALITY OF CORNEAL PIGMENTATION IN PATIENTS WITH 
LENTICULAR PIGMENTATION
Table No - 17
LATERALITY NUMBER OF PATIENTS
Bilateral 11(62.3%)
Unilateral 3(17.6%)
Absent 3(17.6%)
TOTAL 17
           Almost all the patients with grade III to V lenticular pigmentation had 
corneal pigmentation. 
SIGNIFICANCE OF CORNEAL PIGMENTATION WITH 
ASSOCIATED VISUAL DEFECTS
RIGHT EYE – CORNEAL PIGMENTATION – 14 PATIENTS
Table No - 18
VISUAL ACUITY NUMBER OF PATIENTS
6/6p to 6/6 with PH 6/6 2(14.2%)
6/9p to 6/9 with PH 6/6 3(21.4%)
6/12p to 6/12 with PH 6/6 4(28.5%)
6/18p to 6/18 with PH 6/6 3(21.4%)
6/24p to 6/24 0
6/36p to 6/36 0
6/60 to 1/60 1(7%)
TOTAL 14
           Almost 90% of patients had visual acuity of 6/18p to 6/18 that improved 
with  pin  hole  to  6/6.  One  patient  had  decreased  visual  acuity  because  of 
associated alternate divergent squint.
LEFT EYE – SIGNIFICANCE OF CORNEAL PIGMENTATION WITH 
ASSOCIATED VISUAL DEFECTS
LEFT EYE  -  CORNEAL PIGMENTATION  - 16 PATIENTS
Table No - 19
VISUAL  ACUITY NUMBER OF PATIENTS
6/6 to 6/6p with PH 6/6 4 (25%)
6/9 to 6/9p with PH 6/6 2 (12.5%)
6/12 to 6/12p with PH 6/6 2 (12.5%)
6/18 to 6/18p with PH 6/6 6 (37.5%)
6/24 to 6/24p with PH 6/12 2 (12.5%)
TOTAL 16
         More than 85% of corneal pigmentation positive patients had visual 
acuity of 6/18 to 6/18 p and above improved with pin hole to 6/6.
FEMALE PATIENTS
TOTAL NUMBER OF PATIENTS :- 50
DURATION OF STAY
Table No. 20
DURATION OF STAY NUMBER OF PATIENTS
>25 years 4(8%)
20 -25 years 5(10%)
15- 20 years 11(22%)
10 -15 years 7(14%)
5-10 years 7(14%)
2-5 years 9(18%)
6 months -2 years 7(14%)
TOTAL 50
       About 40% of patients in this study are in the hospital for a period of more 
than 15 years.
AGE DISTRIBUTION
Table No. 21
AGE GROUP NUMBER OF PATIENTS
20-30 years 10(20%)
31-40 years 9(18%)
41-50 years 17(34%)
51-60 years 5(10%)
61-70 years 9(18%)
TOTAL 50
About 62 % of patients are more than 40 years.
LIST OF PATIENTS WHO HAD PIGMENTATION OR OPACITIES 
(CORNEAL AND LENTICULAR ) IN GENERAL
Table No. 22
DOSAGE OF 
THERAPY
DURATION OF 
THERAPY
NUMBER OF 
PATIENTS
50-200mgs /day >25 years 3(17.6%)
50-300mgs/day 20-25 years 4(23.5%)
50-200mgs/day 15-20 years 8(47%)
100-300mgs/day 10-15 years 1(5.8%)
100-200mgs/day 5-10 years 1(5.8%)
TOTAL 17
About  47% of  patients  who  had lenticular  and  corneal  pigmentation 
were on tablet chlorpromazine 50- 200 mgs /day for a period of 15-20 years 
Pigmentation was seen as early as 100-200 mgs/day for  5 to 10 years in 1 
patient to as late as 50-200 mgs /day for more than 25 years in 3 patients.
LIST OF PATIENTS WHO DID NOT HAVE PIGMENTATION OR 
OPACITIES (CORNEAL AND LENTICULAR) IN GENERAL
Table No. 23
DOSAGE OF 
THERAPY
DURATION OF 
THERAPY
NUMBER OF 
PATIENTS
50mgs/day >25 years 1(3%)
50-100mgs/day 20-25 years 1(3%)
50-100mgs/day 15-20years 3(9%)
50-100mgs/day 10-15years 6(18%)
50-200mgs/day 5-10years 6(18%)
50-200mgs/day 2-5years 9(36%)
50-100mgs/day 6months -2years 7(21%)
TOTAL 33
Five out of thirty three patients who were on 50 - 100mgs/day for more 
than 15 years did not  have pigmentation .
RIGHT EYE VISUAL ACUITY IN PIGMENTATION OR OPACITY 
(CORNEAL AND LENTICULAR )POSITIVE CASES
Table No. 24
VISUAL ACUITY NUMBER OF PATIENTS
6/6 to 6/6p with PH 6/6 4(23.5%)
6/9 to 6/9p with PH 6/6 1(5.8%)
6/12 to 6/12p with PH 6/6 4(23.5%)
6/18 to 6/18p with PH 6/6 4(23.5%)
6/24 to 6/24p with PH 6/12 3(17.6%)
6/36NIP 1(5.8%)
TOTAL 17
       About 70% had visual acuity of 6/18 to 6/18p improving with pin hole to 
6/6.  The  rest  had  visual  acuity  less  than  6/24  because  of  associated  lens 
changes.
LEFT EYE VISUAL ACUITY IN PIGMENTATION OR OPACITY 
(CORNEAL AND LENTICULAR) POSITIVE CASES
Table No.25
VISUAL ACUITY NUMBER OF PATIENTS
6/6 to 6/6p with PH 6/6 4(23.5%)
6/9 to 6/9p with PH 6/6 2(11.8%)
6/12 to 6/12p with PH 6/6 2(11.8%)
6/18 to 6/18p with PH 6/6 7(41.1%)
6/24 to 6/24p with PH 6/12 2(11.8%)
TOTAL 17
      About 80% had visual acuity of 6/18 to 6/18p improving with pin hole to 
6/6. The rest had visual acuity of 6/24 because of associated lens changes.
RIGHT  EYE VISUAL ACUITY IN PIGMENTATION OR OPACITY 
(CORNEAL AND LENTICULAR) NEGATIVE  CASES
 Table No.26
VISUAL ACUITY NUMBER OF PATIENTS
6/6 to 6/6p with PH 6/6 6(18.1%)
6/9 to 6/9p with PH 6/6 7(21.2%)
6/12 to 6/12p with PH 6/6 8(24.2%)
6/18 to 6/18p with PH 6/6 4(12.1%)
6/24 to 6/24p with PH 6/12 4(12.1%)
6/36 to 6/36p NIP 2(6%)
6/60 to 1/60 NIP 2(6%)
TOTAL 33
       About 77% had visual acuity of 6/18 to 6/18p improving with pin hole to 
6/6. Rest had decreased visual acuity because of associated lens changes.
LEFT EYE VISUAL ACUITY IN PIGMENTATION OR OPACITY 
(CORNEAL AND LENTICULAR ) NEGATIVE CASES
Table No.27
VISUAL ACUITY NUMBER OF PATIENTS
6/6 to 6/6p with PH  6/6 7(21.2%)
6/9 to 6/9p with  PH 6/6 9(27.2%)
6/12 to 6/12p with PH 6/6 6(18.1%)
6/18 to 6/18p with PH  6/6 3(9%)
6/24 to 6/24p with PH 6/12 5(15%)
6/60 to 1/60 NIP 3(9%)
TOTAL 33
       About 76% had visual acuity of 6/18 to 6/18p that was improving with pin 
hole to 6/6. Rest had visual acuity of 6/24 or below because of associated  lens 
changes and immature cataract.
  
LATERALITY  OF LENTICULAR PIGMENTATION
Table No. 28
LATERALITY NUMBER OF PATIENTS
Bilateral 16 (94%)
Unilateral 1(6%)
TOTAL 17
About 94% of patients had bilateral lenticular pigmentation.
RIGHT EYE  -  NO. OF PATIENTS IN VARYING GRADES OF 
LENTICULAR PIGMENTATION AMONG POSITIVE CASES
Table No. 29
GRADES NUMBER OF PATIENTS
V 9 (52.3%)
III 7 (47.7%)
TOTAL 16
      About  52% of patients had Grade V lenticular pigmentation and the rest 
Grade III.
LEFT EYE  -  NO. OF PATIENTS IN VARYING GRADES OF 
LENTICULAR PIGMENTATION AMONG POSITIVE CASES
Table No. 30
GRADES NO. OF PATIENTS
V 11(64.7%)
IV 2 (11.7%)
III 3 (17.6%)
II 1 (5.8%)
TOTAL 17
About 65% patients had Grade V lenticular pigmentation
RIGHT EYE
GRADE   V -  9  PATIENTS
Table No. 31
VISUAL  ACUITY NUMBER OF PATIENTS
6/6 TO 6/6p with PH 6/6 2 (22.2%)
6/12 to 6/12p with PH 6/6 2 (22.2%)
6/18 to 6/18p with PH 6/6 2 (22.2%)
6/24 to 6/24p with PH 6/12 2 (22.2%)
6/36 NIP 1 (11.1%)
TOTAL 9
         About 66% of patients with Grade V lenticular pigmentation had visual 
acuity of 6/18 to 6/18p improving with pin hole to 6/6 .
GRADE    III    -   7  PATIENTS
Table No.32
VISUAL  ACUITY NUMBER OF PATIENTS
6/6 to 6/6p with PH 6/6 2 (28.5%)
6/9  with PH 6/6 1 (14.2%)
6/12 to 6/12p with PH 6/6 2 (28.5%)
6/18  with PH 6/6 1 (14.2%)
6/24 with  PH 6/12 1 (14.2%)
TOTAL 7
         About 85% of patients with Grade III lenticular pigmentation had visual 
acuity of 6/18 to 6/18p improving with pin hole to 6/6.
LEFT EYE
GRADE   V   -    11   PATIENTS
Table No - 33
VISUAL  ACUITY NUMBER OF PATIENTS
6/6 to 6/6p with PH 6/6 3 (27.2%)
6/12 to 6/12p with PH 6/6 2 (18.1%)
6/18 to 6/18p with PH 6/6 5 (45.5%)
6/24 with PH 6/12 1 (9%)
TOTAL 11
About 90% of patients with Grade V lenticular pigmentation had visual 
acuity of 6/18 to 6/18p improving with pin hole to 6/6.
GRADE    III -   3   PATIENTS
Table No- 34
VISUAL  ACUITY NUMBER OF PATIENTS
6/6p with PH 6/6 1 (33%)
6/9 to 6/9p with PH 6/6 2 (66%)
TOTAL 3
GRADE   IV   - 2  PATIENTS
Table No- 35
VISUAL ACUITY NUMBER OF PATIENTS
6/18 with PH 6/6 1 (50%)
6/24 with PH 6/12 1 (50%)
TOTAL 2
GRADE  II   -1   PATIENT :  6/18p with pin hole 6/6 .
LATERALITY OF CORNEAL PIGMENTATION IN PATIENTS WITH 
LENTICULAR PIGMENTATION
Table No -  36
LATERALITY NUMBER OF PATIENTS
Bilateral 14 ( 82% )
Unilateral 2 ( 11.7%)
Absent 1 (5.9%)
TOTAL 17
RIGHT EYE  - SIGNIFICANCE OF CORNEAL PIGMENTATION 
WITH ASSOCIATED VISUAL DEFECT
RIGHT EYE CORNEAL  PIGMENTATION  - 14 PATIENTS
Table No - 37
VISUAL  ACUITY NUMBER OF PATIENTS
6/6 to 6/6p with PH 6/6 4 (28.5%)
6/9  with PH 6/6 1 (7.1%)
6/12 to 6/12p with PH 6/6 4 (28.5%)
6/18 to 6/18p with PH to 6/6 4(28.5%)
6/36  with PH 6/12 1 (7.1%)
TOTAL 14
        About 92% of patients who had corneal pigmentation, had visual acuity of 
6/18 to 6/18p improving with pin hole to 6/6.
LEFT EYE – SIGNIFICANCE OF CORNEAL PIGMENTATION WITH 
ASSOCIATED VISUAL DEFECT
LEFT EYE   -  CORNEAL PIGMENTATION   16 PATIENTS
Table No - 38
VISUAL  ACUITY NUMBER OF PATIENTS
6/6 to 6/6p with PH 6/6 4 (25%)
6/9 to 6/9p with PH 6/6 2 (12.5%)
6/12 to 6/12p with PH 6/6 2 ( 12.5%)
6/18 to 6/18p with PH 6/6 6 (37.5%)
6/24 to 6/24p with PH 6/12 2 (12.5%)
TOTAL 16
More  than  80% of  corneal  pigmentation  positive  patients  had  visual 
acuity of 6/18 to 6/18p improving with pin hole to 6/6.
DISCUSSION
         The ocular changes associated with chlorpromazine therapy are dose  
related.
         The most prevalent ocular side effects associated with chlorpromazine 
therapy are anterior capsular and subcapsular pigmentation followed by corneal 
endothelial  pigmentary  changes.  Both conditions do not  affect  visual  acuity 
significantly.  (Ref-  Clinical  Ocular  pharmacology-fourth  edition-Jimmy 
D.Barlett Siret D.jaanus)
        This study has been directed towards detecting the incidence of corneal 
and lenticular pigmentation or opacities in 100 mentally ill  patients on     
 T. Chlorpromazine for more than 6 months period.
MALE PATIENTS
     The majority of male patients are in the age group 41- 50 years and they 
have been hospitalized as inpatients for more than 10 years .
     Up  to  34%  of  patients  had  corneal  and  lenticular  pigmentation  or 
opacities. Among the patients who had pigmentation or opacities, 53% are on 
T. Chlorpromazine 100-200mg/day for more than 10 years.
 The right  eye visual  acuity  in  pigmentation positive  cases  is  6/18 to 
6/18p and above, improved with pin hole to 6/6 in 58% of patients.
     The left eye visual acuity in pigmentation positive cases is 6/18 to 6/18p 
and above, improved with pin hole to 6/6 in 80% of patients.
The right eye visual acuity in pigmentation negative cases is 6/18 to 
6/18p and above, improved with pin hole to 6/6 in 69% of  patients.
The left eye visual acuity in pigmentation negative cases is 6/18 to 6/18p 
and above, improved with pin hole to 6/6 in  80 % of patients.
About 66% of patients did not have pigmentary changes. Even 21% of 
patients who are on 50-200mg /day for more than 10 years did not develop 
pigmentary changes for which highly restricted out door activity is supposed to 
be the associated factor.
 In 76% of the patients lenticular pigmentary changes are bilateral.
About 56% of patients with Grade V lenticular pigmentation had visual 
acuity of 6/18 to 6/18p and above, improved with pin hole to 6/6 in right eye 
and almost all patients with Grade V lenticular pigmentation had visual acuity 
of 6/18 to 6/18p and above, improved with pin hole to 6/6 in left eye.
     Almost  90% of  patients  with corneal  pigmentary  changes  had visual 
acuity of 6/18 to 6/18p and above, improved with pin hole to 6/6 in both eyes.
FEMALE PATIENTS
      The majority of female patients are in the age group 41-50 yrs and about 
22% of them were residing as inpatients for more than 15 years.
The Right eye visual acuity in pigmentation positive cases is 6/18 to 
6/18p and above, improved with pin hole to 6/6 in about 70% of patients.
      The left eye visual acuity in pigmentation positive cases is 6/18 to 6/18p 
and above, improved with pin hole to 6/6 in about 80% of patients.
The right eye visual acuity in pigmentation negative cases is 6/18 to 
6/18p and above, improved with pin hole to 6/6 in about 77 % of patients.
     The left eye visual acuity in pigmentation negative cases is 6/18 to 6/18p 
and above, improved with pin hole to 6/6 in about 76% of patients.
About 66% of patients in the study did not have pigmentary changes. 
Even 33% of patients  on T.  Chlorpromazine 50-100mg/day for  more than  
10 years did not have pigmentary changes for which highly restricted out door 
activity is supposed to be the associated factor.
 About  94%  of  patients  had  bilateral  lenticular  pigmentary  changes 
About 66% of patients in grade V lenticular pigmentation had visual acuity of 
6/18 to 6/18p and above, improved with pin hole to 6/6 in right eye and about 
90% of patients in grade V lenticular pigmentation had visual acuity of 6/18 to 
6/18p and above, improved with pin hole to 6/6 in left eye.
Almost  90% of  patients  with corneal  pigmentary  changes  had visual 
acuity of 6/18 to 6/18p and above, improved with pin hole to 6/6.
Some  patients  in  the  study  are  having  age  related  lens  changes, 
traumatic  cataract,  adherent  leucoma  and  alternate  divergent  squint,  which 
might be the reasons for the significant visual loss.
In general, the lenticular and corneal pigmentary changes did not affect 
visual acuity significantly.
SUMMARY
-   This clinical study was done at Institute of mental health, Ayanavaram.
-  A total of 100 mentally ill  patients were evaluated, 50 male and 50 
female patients.
-  Relevant data collected from each patients and they were subjected to a 
detailed ophthalmic evaluation.
- 32% of males were in age group 31– 40 years and 34% of females were 
in age group 41-50 years.
- 30% of males were on Chlorpromazine therapy for a period of 10-15 
years and 22% of females for 15-20 years.
- Male patients who were on T.Chlorpromazine 100-200mg/day for more 
than 10 years had significant lenticular and corneal pigmentary changes.
- Female patients who were on T.Chlorpromazine 50-200mg/day for more 
than 15 years had significant lenticular and corneal pigmentary changes.
- The difference in pigmentary changes with dose and duration of therapy 
between  males  and  females  is  probably  due  to  restricted  out  door 
activity in the later. An accepted hypothesis for pigmentary granules is 
that pigmentary changes are a result of drug interactions with UV light 
as it passes through the cornea and lens, causing  exposed proteins  to 
denature, opacify and accumulate in the anterior subcapsular  region  of 
the lens as well as stroma. 
- Most patients had grade III to grade V lenticular pigmentary changes.
- Corneal pigmentary changes are seen in more than 95 % of patients with 
grade III to grade V lenticular pigmentary changes.
- The lenticular and corneal pigmentary changes as such did not affect 
visual acuity significantly 
- The  lenticular  pigmentation  was  seen  in  anterior  capsular  and 
subcapsular region followed by corneal endothelial pigmentary changes, 
confined to interpalpebral fissure area.
CONCLUSION
- Lenticular and corneal pigmentary changes are the most significant 
ocular  side  effects  of  long  term therapy  with  Chlorpromazine  in 
mentally ill patients.
- Detailed ophthalmological evaluation by an ophthalmologist should 
be made mandatory before starting a patient on Chlorpromazine.
- Patients  on  long  term  Chlorpromazine  should  be  subjected  for 
detailed ophthalmic evaluation periodically (Every 2 years in first 10 
years and annually thereafter. If the dosage is more than 200mg/day, 
evaluation should be done in annual basis).
- The present scenario in rehabilitating the mentally ill patients, other 
specialist like Ophthalmologist should also play a major role with 
Psychiatrist to make the patients in leading a dignified independent 
life.
TEAM APPROACH YIELDS BETTER RESULTS
EVERY WHERE
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PROFORMA
1.  NAME 
2. AGE    
3. SEX
4. OCCUPATION
5. ADDRESS
6. PSYCHIATRIC DIAGNOSIS
         a. SCHIZOPHRENIA -VARIOUS SUB TYPES
         b. MILD MENTAL RETARDATION WITH BEHAVIOURAL 
             PROBLEM
         c. BIPOLAR DISORDERS
         d. SUBSTANCE INDUCED PSYCHOSIS ( ALCOHOL/ 
             CANNABIS)
7.CHLORPROMAZINE-  a. DOSAGE OF THERAPY
                                           b. DURATION OF THERAPY
                                           c. MULTI DRUG   REGIMEN
                                                                      1. Name of drug / drugs
                                                                      2. Dosage and duration of drugs
8. PAST HISTORY
9. FAMILY HISTORY
GENERAL EXAMINATION 
                1. Built and Nourishment
                2.Anaemia, Jaundice, Cyanosis, Clubbing, Lymphadenopathy
CARDIO VASCULAR SYSTEM
RESPIRATORY SYSTEM
CENTRAL NERVOUS SYSTEM
ABDOMEN
RIGHT EYE LEFT EYE
VISUAL  ACUITY  (UNAIDED AND 
WITH PH)
OCULAR MOVEMENTS
LIDS
CONJUNCTIVA
CORNEA
ANTERIOR CHAMBER
IRIS
PUPIL
LENS
TENSION
SLIT LAMP EXAMINATION
FUNDUS
OPERATIONS PERFORMED
S.
NO DATE NAME
AGE /
SEX
DIAGNOSIS PROCEDURE
1. 10/07/04 KAVITHA 15/F LE-Upper lid 
chalazion
LE-I&C done
2. 07/08/04 KUPPU 28/F RE-Nasal 
pterygium
RE-Pterygium 
excision done
3. 23/08/04 ANGAMMAL 70/F RE-Mature 
cataract
RE-ECCE with 
PCIOL done
4. 16/09/04 MANI 68/M LE-Mature 
cataract
LE-ECCE with 
PCIOL done
5. 28/10/04 CHINNAMMAL 66/F RE-Mature 
cataract
RE-ECCE with 
PCIOL done
6. 18/09/04 PRAKASH 35/M LE-Upper lid
chalazion
LE-I&C done
7. 02/03/05 KANAGAVALLI 55/F RE-Mature 
cataract
RE-ECCE with 
PCIOL
8. 25/04/05 INDRANI 60/F RE-Chronic 
Dacryocystitis
RE-DCT done
9. 05/05/05 PERUMAL 80/F LE-Mature 
cataract
LE-ECCE with 
PCIOL done
10. 28/06/05 DEVAKI 60/F LE-Immature 
cataract
LE-ECCE with 
PCIOL done
11. 13/08/05 KILIAMMAL 60/F LE-Painful blind 
eye due ti\o mixed 
corneal ulcer
LE-Evisceration 
done
12. 05/09/05 RAMASAMY 62/M LE-Chronic 
Dacryocystitis
LE-DCT done
13. 19/10/05 DHANAPAL 54/M RE-Nuclear 
cataract
RE-ECCE with 
PCIOL done
14. 27/12/05 VASU 23/M RE-Nasal & 
Temporal 
pterygium
RE-Pterygium 
excision done
15. 06/01/06 KUMAR 50/M RE-Mature 
cataract
RE-ECCE with 
PCIOL done
16. 24/02/06 MUTHAMMAL 50/F RE-Immature RE-ECCE with 
S.
NO DATE NAME
AGE /
SEX
DIAGNOSIS PROCEDURE
cataract PCIOL done
17. 03/05/06 SHEKDAVUDMA 75/F LE-Immature 
cataract
LE-SICS with 
PCIOL done
18. 02/06/06 KASTHURI 67/F LE-Immature 
cataract
LE-SICS with 
PCIOL done
19. 03/07/06 AZHAGUTHAI 50/F LE-Immature
cataract
LE-SICS with 
PCIOL done
20. 28/07/06 RAMAYEE 54/F LE-Nuclear 
cataract
LE-ECCE with 
PCIOL done
21. 04/08/06 ANDALAMMAL 60/F RE-Immature 
cataract
RE-SICS with 
PCIOL done
22. 04/08/06 RANGANATHAN 63/M LE-Immature 
cataract
LE-SICS with 
PCIOL done
23. 28/08/06 RAJU 70/M LE-Immature 
cataract
LE-SICS with 
PCIOL done
24. 01/09/06 KODEESWARI 64/F LE-Immature 
cataract
LE-SICS with 
PCIOL done
25. 08/09/06 NARAYANAN 75/M RE-Immature 
cataract
RE-SICS with 
PCIOL done
KEY TO MASTER CHART
     m   -  male
     f    -  female
     CP -  Corneal pigmentation
      P  -  Present
     A  -  Absent
    LP - Lenticular pigmentation
Grades
      I  -  Fine,dot like  opacities on anterior lens capsule
      II - Dot like opacities denser and more opaque
      III - Large granules of pigment with an anterior subcapsular stellate pattern
      IV - Readily visible stellate pattern with three to nine star points
      V - Central lightly pigmented, pearl like opaque mass surrounded by 
             smaller granules of pigment
     V/A- Visual acuity
      p - Partial
     PH - Pinhole
     RE - Right eye
     LE - Left eye
     E - Emmetropia
     LC - Lens changes
     IMC - Immature Cataract
     TR.CA - Traumatic cataract
PATIENTS WHO HAD PIGMENTATION 
MALE AND FEMALE (FEW PICTURES)



LENTICULAR PIGMENTATION
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